540694 — ANG Lifesciences India Income Statement
0.000.00%
- IN₹642.21m
- IN₹1.20bn
- IN₹1.46bn
- 37
- 62
- 13
- 27
Annual income statement for ANG Lifesciences India, fiscal year end - March 31st, INR millions except per share, conversion factor applied.
2020 March 31st | 2021 March 31st | 2022 March 31st | 2023 March 31st | 2024 March 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | ARS | ARS | ARS | ARS | PRESS |
Standards: | IAS | IAS | IAS | IAS | — |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 1,268 | 1,544 | 3,543 | 2,199 | 1,461 |
Cost of Revenue | |||||
Gross Profit | 379 | 504 | 1,263 | 621 | 510 |
Selling / General / Administrative Expenses | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 1,160 | 1,418 | 2,927 | 2,064 | 1,466 |
Operating Profit | 109 | 125 | 616 | 135 | -4.55 |
Gain / Loss on Sale of Assets | |||||
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | 84.1 | 101 | 535 | 26.3 | -107 |
Provision for Income Taxes | |||||
Net Income After Taxes | 61 | 70.3 | 403 | -2.62 | -101 |
Net Income Before Extraordinary Items | |||||
Net Income | 61 | 70.3 | 403 | -2.62 | -101 |
Adjustments to Net Income | |||||
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | 61 | 70.3 | 403 | -2.62 | -101 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | 4.7 | 5.42 | 31.2 | -4.73 | -6.76 |
Dividends per Share |